联环药业(600513.SH)子公司获得美阿沙坦钾片药品注册证书

Core Viewpoint - The company has received a drug registration certificate for Benazepril Potassium Tablets, which will enhance its product line and market competitiveness [1] Group 1: Company Developments - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration for the registration of Benazepril Potassium Tablets [1] - The approved dosage forms are 40mg and 80mg, which are intended for the treatment of adult primary hypertension [1] - The acquisition of the drug registration certificate is expected to enrich the product line of the company and its subsidiaries [1] Group 2: Market Impact - The approval is anticipated to improve the market competitiveness of the company's products [1] - The company does not expect a significant impact on its recent operating performance from this approval [1]